blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3893887

EP3893887 - LXR AGONIST IN TOPICAL OPHTHALMIC FORMULATION FOR TREATMENT OF DRY-EYE DISORDER [Right-click to bookmark this link]
StatusThe application has been withdrawn
Status updated on  05.01.2024
Database last updated on 30.10.2024
FormerRequest for examination was made
Status updated on  17.09.2021
FormerThe international publication has been made
Status updated on  20.06.2020
Most recent event   Tooltip05.01.2024Withdrawal of applicationpublished on 07.02.2024  [2024/06]
Applicant(s)For all designated states
Eyenos, Inc.
1162 S. Oak Park Ave, Apt A
Oak Park, Illinois 60304 / US
[2021/42]
Inventor(s)01 / KAJA, Simon
511 Windett Ridge Rd.
Yorkville, 60560 / US
02 / GHOSH, Anita
1162 S. Oak Park Ave., Apt 1
Oak Park, 60304 / US
03 / JONES, Walter Keith
3591 Harmony Cir.
Elgin, 60124 / US
 [2021/42]
Representative(s)AWA Denmark A/S
Strandgade 56
1401 Copenhagen K / DK
[2021/42]
Application number, filing date19895681.512.12.2019
[2021/42]
WO2019US66074
Priority number, dateUS201862779330P13.12.2018         Original published format: US 201862779330 P
[2021/42]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2020123869
Date:18.06.2020
Language:EN
[2020/25]
Type: A1 Application with search report 
No.:EP3893887
Date:20.10.2021
Language:EN
The application published by WIPO in one of the EPO official languages on 18.06.2020 takes the place of the publication of the European patent application.
[2021/42]
Search report(s)International search report - published on:US18.06.2020
(Supplementary) European search report - dispatched on:EP01.12.2022
ClassificationIPC:A61K31/18, A61K31/195, A61P27/04, A61K9/00, A61K9/10, A61K9/51, A61F9/00
[2023/01]
CPC:
A61K31/18 (EP,US); A61K9/0048 (EP,US); A61F9/0008 (EP,US);
A61K31/195 (EP,US); A61K9/10 (EP); A61K9/5153 (EP,US);
A61P27/04 (EP,US) (-)
Former IPC [2021/42]A61K31/575, A61K31/18, A61K31/19, A61P27/02
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2021/42]
TitleGerman:LXR-AGONIST IN TOPISCHER OPHTHALMISCHER FORMULIERUNG ZUR BEHANDLUNG DES TROCKENEN AUGES[2021/42]
English:LXR AGONIST IN TOPICAL OPHTHALMIC FORMULATION FOR TREATMENT OF DRY-EYE DISORDER[2021/42]
French:AGONISTE DES LXR DANS UNE FORMULATION OPHTALMIQUE TOPIQUE POUR LE TRAITEMENT D' UN SYNDROME DE L'OEIL[2021/42]
Entry into regional phase09.07.2021National basic fee paid 
09.07.2021Search fee paid 
09.07.2021Designation fee(s) paid 
09.07.2021Examination fee paid 
Examination procedure09.07.2021Examination requested  [2021/42]
10.01.2022Loss of particular rights, legal effect: Claims
02.03.2022Despatch of communication of loss of particular rights: Claims {1}
10.03.2023Amendment by applicant (claims and/or description)
04.01.2024Application withdrawn by applicant  [2024/06]
Fees paidRenewal fee
24.11.2021Renewal fee patent year 03
17.11.2022Renewal fee patent year 04
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[A]  - PFLUGFELDER STEPHEN C ET AL, "The Pathophysiology of Dry Eye Disease What We Know and Future Directions for Research", OPHTHALMOLOGY, (20171101), vol. 124, no. 11, doi:10.1016/J.OPHTHA.2017.07.010, ISSN 0161-6420, XP085223256 [A] 1-15 * the whole document *

DOI:   http://dx.doi.org/10.1016/j.ophtha.2017.07.010
International search[A]US2003162758  (SCHWARTZ DANIEL M [US], et al) [A] 1-20* Entire Document *;
 [Y]US2006094643  (SVIRKIN YURI [US], et al) [Y] 14-15, 19-20 * para [0001], [0139]-[0141] *;
 [A]US2015031655  (GHRIBI OTHMAN [US]) [A] 1-20 * Entire Document *;
 [Y]US2015140106  (MOUSA SHAKER A [US]) [Y] 2-4, 16-20 * para [0007], [0013]-[0016], [0024], [0031], [0061]-[0062], [0077] *;
 [XY]WO2015187840  (UNIV DUKE [US]) [X] 1, 5-7, 9-13 * para [0007]-[0008], [0047]-[0048], [0084], [00100], [00103] * [Y] 2-4, 8, 14-20;
 [Y]  - TAMURA et al., "Ouabagenin is a naturally occurring LXR ligand without causing hepatic steatosis as a side effect", Scientific Reports, vol. 8, (20180202), pages 1 - 15, XP055720457 [Y] 8 * . Abstract; Figure 1; pg 6, para 2-para 5 *

DOI:   http://dx.doi.org/10.1038/s41598-018-20663-z
 [A]  - YANG et al., "Activation of Liver X Receptor Alleviates Ocular Inflammation in Experimental Autoimmune Uveitis", IOVS, (20140000), vol. 55, no. 4, pages 2795 - 2804, XP055720458 [A] 1-20 * . Entire Document *

DOI:   http://dx.doi.org/10.1167/iovs.13-13323
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.